{
    "clinical_study": {
        "@rank": "87157", 
        "acronym": "MILES-4", 
        "arm_group": [
            {
                "arm_group_label": "A: Gemcitabine", 
                "arm_group_type": "Active Comparator", 
                "description": "Single agent gemcitabine dose 1200 mg/m2 days 1 and 8, every 3 weeks"
            }, 
            {
                "arm_group_label": "B:  Gemcitabine + Cisplatin", 
                "arm_group_type": "Experimental", 
                "description": "Gemcitabine dose 1000 mg/m2 days 1 and 8, every 3 weeks"
            }, 
            {
                "arm_group_label": "C:  Pemetrexed", 
                "arm_group_type": "Active Comparator"
            }, 
            {
                "arm_group_label": "D: Pemetrexed + Cisplatin", 
                "arm_group_type": "Experimental"
            }
        ], 
        "brief_summary": {
            "textblock": "The purposes of this study are to test whether the addition of cisplatin to single agent\n      chemotherapy (either gemcitabine or pemetrexed) prolongs survival in elderly patients with\n      non squamous non small cell lung cancer (NSCLC), and to test whether pemetrexed prolongs\n      survival as compared to gemcitabine in elderly patients with non squamous NSCLC."
        }, 
        "brief_title": "Study Comparing Gemcitabine and Pemetrexed, With or Without Cisplatin, in Patients With Nonsquamous Lung Cancer", 
        "completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Non-small Cell Lung Cancer Metastatic", 
            "Non-small Cell Lung Cancer Stage IIIB"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma, Non-Small-Cell Lung", 
                "Lung Neoplasms", 
                "Neoplasms"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Diagnosis of cytologically or histologically confirmed non-small cell lung cancer.\n\n          -  Non squamous tumor type (including those with a non-specified tumor type).\n\n          -  Metastatic (stage IV, both M1A or M1B) or locally advanced (stage IIIB, with\n             metastasis to supraclavicular nodes) according to TNM VII edition.\n\n          -  Both patients at first diagnosis or those with disease recurrence after former\n             surgery are eligible.\n\n          -  At least one target or non-target lesion according to RECIST revised version 1.1.\n\n          -  Male or female > or = 70 years of age.\n\n          -  ECOG PS 0 or 1.\n\n          -  Life expectancy > 3 months.\n\n          -  Neutrophils > or = 1500 mm3, platelets > or = 100000 mm3, and haemoglobin > or = 9\n             g/dL.\n\n          -  Bilirubin level either normal or < 1.5 x ULN.\n\n          -  AST (SGOT) and ALT (SGPT) < or = 2.5 x ULN (< or = 5 x ULN if liver metastasis are\n             present).\n\n          -  Serum creatinine  < 1.5 x ULN.\n\n          -  Signed written informed consent.\n\n        Exclusion Criteria:\n\n          -  Prior chemotherapy or therapy with systemic anti-neoplastic therapy for advanced\n             disease. Prior surgery and/or localised irradiation is permitted. Prior adjuvant\n             chemotherapy is permitted if it did not contain gemcitabine and pemetrexed and if at\n             least 6 months elapsed from the end of adjuvant chemotherapy.\n\n          -  Any unstable systemic disease (including active infections, significant\n             cardiovascular disease or myocardial infarction within the previous year, any\n             significant hepatic, renal or metabolic disease), metabolic dysfunction, physical\n             examination finding, or clinical laboratory finding that contraindicates the use of\n             study medications or render the patient at high risk from treatment complications.\n\n          -  Any other malignancies within 5 years (except for adequately treated carcinoma in\n             situ of the cervix or basal or squamous cell skin cancer or surgically resected\n             prostate cancer with normal PSA).\n\n          -  Patients with symptomatic brain metastasis or spinal cord compression that has not\n             yet been treated with surgery and/or radiation; patients with CNS metastases or\n             spinal cord compression previously treated with surgery and/or radiation are eligible\n             if they are asymptomatic and do not require steroids (anti-seizure medications are\n             allowed).\n\n          -  Known or suspected hypersensitivity to any of the study drugs"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "70 Years"
        }, 
        "enrollment": {
            "#text": "550", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 23, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01656551", 
            "org_study_id": "MILES-4", 
            "secondary_id": "2012-000164-25"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "A: Gemcitabine", 
                    "B:  Gemcitabine + Cisplatin"
                ], 
                "intervention_name": "Gemcitabine", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "C:  Pemetrexed", 
                    "D: Pemetrexed + Cisplatin"
                ], 
                "description": "500 mg/m2 day 1 every 3 weeks", 
                "intervention_name": "Pemetrexed", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "B:  Gemcitabine + Cisplatin", 
                    "D: Pemetrexed + Cisplatin"
                ], 
                "description": "60 mg/m2 day 1 every 3 weeks", 
                "intervention_name": "Cisplatin", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Gemcitabine", 
                "Pemetrexed", 
                "Cisplatin"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "elderly", 
            "chemotherapy"
        ], 
        "lastchanged_date": "January 2, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Avellino", 
                        "country": "Italy"
                    }, 
                    "name": "S. Giuseppe Moscati"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Brindisi", 
                        "country": "Italy"
                    }, 
                    "name": "Ospedale Senatore Antonio Perrino"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Campobasso", 
                        "country": "Italy"
                    }, 
                    "name": "Ospedale A. cardarelli"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Carpi", 
                        "country": "Italy"
                    }, 
                    "name": "Ospedale Ramazzini di Carpi"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Catania", 
                        "country": "Italy"
                    }, 
                    "name": "Azienda Ospedaliera Garibalda Nesimadi Catania"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Frosinone", 
                        "country": "Italy"
                    }, 
                    "name": "Ospedale Fabrizio Spaziani"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Genova", 
                        "country": "Italy"
                    }, 
                    "name": "Ospedale Villa Scassi"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Guastalia", 
                        "country": "Italy"
                    }, 
                    "name": "Ospedale di Guastalia"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Lecce", 
                        "country": "Italy"
                    }, 
                    "name": "Azienda Ospedaliera Vito Fazzi"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Milano", 
                        "country": "Italy"
                    }, 
                    "name": "Ospedale S. Paolo"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Mirano", 
                        "country": "Italy"
                    }, 
                    "name": "U.L.S.S. 13"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Napoli", 
                        "country": "Italy"
                    }, 
                    "name": "Istituto Nazionale dei Tumori"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Padova", 
                        "country": "Italy"
                    }, 
                    "name": "Istituto Oncologico Veneto"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Palermo", 
                        "country": "Italy"
                    }, 
                    "name": "Azienda Ospedaleira Ospedali Riuniti Villa Sofia Cervello"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Pavia", 
                        "country": "Italy"
                    }, 
                    "name": "Fondazione Salvatore Maugeri"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Potenza", 
                        "country": "Italy"
                    }, 
                    "name": "A.O. San Carlo"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "S. Giovanni Rotondo", 
                        "country": "Italy"
                    }, 
                    "name": "Oncologia IRCCS - Casa Sollievo Sofferenza"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Saliceto", 
                        "country": "Italy"
                    }, 
                    "name": "Ospedale Guglielmo da Saliceto-USL di Piacenza"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sondrio", 
                        "country": "Italy"
                    }, 
                    "name": "Ospedale di Sondrio"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sora", 
                        "country": "Italy"
                    }, 
                    "name": "Ospedale SS. Trinit\u00e0"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Viterbo", 
                        "country": "Italy"
                    }, 
                    "name": "ASL Viterbo Ospedale Belcolle"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Italy"
        }, 
        "number_of_arms": "4", 
        "official_title": "A Factorial Study Comparing Pemetrexed With Gemcitabine and Testing the Efficacy of the Addition of Cisplatin in Elderly Patients With Non Squamous Advanced, Metastatic or Recurrent NSCLC.", 
        "other_outcome": [
            {
                "measure": "identification of patient and lesion specific prognostic factors", 
                "safety_issue": "No", 
                "time_frame": "2 years"
            }, 
            {
                "measure": "identification of patient and lesion specific factors predictive of chemotherapy efficacy", 
                "safety_issue": "No", 
                "time_frame": "2 years"
            }
        ], 
        "overall_contact": {
            "email": "francesco.perrone@usc-intnapoli.net", 
            "last_name": "Francesco Perrone, M.D., Ph.D.", 
            "phone": "+39 081 5903571"
        }, 
        "overall_contact_backup": {
            "email": "massimo.dimaio@usc-intnapoli.net", 
            "last_name": "Massimo Di Maio, M.D.", 
            "phone": "+39 081 5903383"
        }, 
        "overall_official": [
            {
                "affiliation": "S.G. Moscati Hopital, Avellino, Italy, Division of Medical Oncology", 
                "last_name": "Cesare Gridelli, M.D.", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "National Cancer Institute Naples, Italy;  Director Clinical Trials Unit", 
                "last_name": "Francesco Perrone, M.D., Ph.D", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Second University of Naples, Italy; Chair of Medical Statistics", 
                "last_name": "Ciro Gallo, M.D., Ph.D", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "National Cancer Institute, Naples", 
                "last_name": "Massimo Di Maio, M.D.", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Italy: Ethics Committee", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "January 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "factorial design with two comparisons:  single agent chemotherapy versus chemotherapy plus cisplatin (Arms A+C versus Arms B + D), and gemcitabine versus pemetrexed (Arms A+B versus Arms C+D)", 
            "measure": "overall survival", 
            "safety_issue": "No", 
            "time_frame": "one year"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01656551"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "according to Common Toxicity Criteria for Adverse Events v. 4.03", 
                "measure": "worst grade toxicity per patient", 
                "safety_issue": "Yes", 
                "time_frame": "evaluated at end of each 3 week cycle of chemotherapy up to 18 weeks"
            }, 
            {
                "measure": "progression free survival", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "measure": "changes in quality of life", 
                "safety_issue": "No", 
                "time_frame": "baseline and up to 18 weeks"
            }, 
            {
                "measure": "objective response", 
                "safety_issue": "No", 
                "time_frame": "after 9 and 18 weeks of therapy"
            }
        ], 
        "source": "National Cancer Institute, Naples", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "National Cancer Institute, Naples", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "July 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}